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Human papillomavirus (HPV) vaccine uptake among 18–26 y old women varies by geographic region in the US.
However, little is known about regional variations in vaccination among girls who are in the vaccine’s targeted age
groups. Regional variation in HPV vaccination among female adolescents (9–17 y old) was examined using cross-
sectional data from the Behavioral Risk Factor Surveillance System (BRFSS) between 2008 and 2010. Multivariable
logistic regression estimated the association of region of residence (10 states included questions about adolescent HPV
vaccination) with uptake and completion of the 3-shot HPV vaccine series. Among 7,849 adolescents, 26.9% initiated,
and 55.2% of initiators completed the series. Adolescents from Northeast/Midwest/West states were 1.74 (95% CI: 1.45-
2.10) times more likely to have initiated HPV vaccination compared to the South/Southwestern states. Among initiators,
vaccine series completion did not vary significantly between the South/Southwestern and Northeast/Midwest/West
states. Flu vaccination was associated with increased odds of initiation in both regions and completion of the HPV
vaccine series in the South/Southwestern states only. Girls 9–10 and 11–12 y old were less likely to have initiated and
11–12 y olds were less likely to have completed the HPV vaccine series compared to 13–17 y olds. The observed
regional variations in vaccination could cause rates of cervical cancer to remain higher in the South/Southwest and
widen currently observed regional disparities in cervical cancer rates.
Introduction
A high rate of human papillomavirus (HPV) vaccination
across the US is expected to significantly reduce the cases of cervi-
cal cancer, precancerous cervical lesions, and other HPV-related
cancers.1 There are currently 2 vaccines approved for use in the
US: the bivalent HPV vaccine, which protects against 2 types of
high-risk HPV, and the quadrivalent vaccine, which protects
against HPV types 6, 11, 16, and 18. HPV types 6 and 11 are
responsible for up to 90% of genital warts, and HPV types 16
and 18 are responsible for 70% of cervical cancers and a high
proportion of other HPV-related anogenital and oral cancers.2-5
While both vaccines have been shown to be efficacious, a very
high proportion of girls need to receive the vaccine to provide a
significant level of herd immunity.6 To achieve this, Healthy
People 2020, which is a program that provides objectives for
improving the health of all Americans, adopted a goal of 80%
coverage with 3-doses of the HPV vaccine among 13–15 y old
females by 2020 (objective IID-11.4).7 Unfortunately, in the
US, there have been low levels of vaccination, particularly in the
southern states where a high proportion of cervical cancer cases
are expected to occur in 2014.8
Regional disparities in HPV vaccination have been observed
in the South among 18–26 y old females compared to other
regions of the US.9 Data from the National Immunization Sur-
vey-Teen (NIS-Teen) has also indicated that 13–17 y olds in the
South have lower rates of HPV vaccination.10 However, less is
known about regional vaccination among younger girls, particu-
larly those who are 11–12 y of age, which is the age range recom-
mended for vaccination. Further, little is known about how
characteristics of vaccination differ in southern states compared
to the rest of the US. States in the South experience a cervical
cancer incidence rate of 10.1 per 100,000 in comparison with
8.9 per 100,000 women in the entire US.11 Unfortunately, ele-
vated rates of cervical cancer in the South indicate that low vacci-
nation levels may contribute to a continued trend in regional
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cervical cancer disparities. An examination of how characteristics
associated with vaccination differ in the South compared to other
regions may contribute to understanding why rates of vaccination
are low in this region.
It is particularly important to understand whether regional
differences in HPV vaccination-both initiation and completion-
are apparent among young adolescents because this is the group
that has been specifically targeted for vaccination by the Advisory
Committee on Immunization Practices (ACIP). The goal of this
study was to examine regional variation in HPV vaccination
among 9–17 y olds by comparing vaccine initiation and comple-
tion rates of Southern states with other states that participated in
the child HPV vaccination module for the Behavioral Risk Factor
Surveillance System (BRFSS) survey.
Results
Overall, using weighted proportions, 26.9% of adolescents in
the BRFSS initiated HPV vaccination and 55.2% of initiators
completed the series. Vaccine initiation prevalence for 13–17 y
olds was 33.9% in 2008, 35.2% in 2009, and 42.0% in 2010.
For the same age group, completion among initiators was 43.9%
in 2008, 58.9% in 2009, and 64.8% in 2010. The proportion of
female children who initiated the HPV vaccine differed depend-
ing on the respondent’s: sex, relationship with the child, insur-
ance status, whether they had a primary care doctor, marital
status, and employment status (Table 1). HPV vaccine initiation
differed by age, but not race/ethnicity. Initiation also varied by
region and flu vaccination status. Completion of the vaccine
series varied by: respondent’s employment status, child’s age,
region, and survey year. Completion of the HPV vaccine series
among initiators differed marginally by region.
Three models are presented to show the separate associations
of the respondent and child characteristics to initiation, with the
final model including all information (Table 2). Children in the
Northeast/Midwest/West were more likely to have initiated vac-
cination compared to children in the South/Southwest. Black
and Hispanic children were more likely to have initiated com-
pared to white children in Model 1, but the association was atten-
uated for black children in the full model (Model 3). Younger
children were less likely to initiate vaccination compared to 13–
17 y old teens. Respondents without a primary care doctor were
less likely to report vaccine initiation compared to those with
one. Flu vaccination was associated with HPV vaccine initiation.
Similar to the presentation of the analyses for initiation, the
associations between respondent and child characteristics are pre-
sented separately in the first 2 models before including all infor-
mation in the final model (Table 3). Analyses for HPV vaccine
series completion revealed that younger girls in the vaccine age
target range (11–12 y of age) were less likely to complete the
HPV vaccine series compared to 13–17 y olds(Model 3). Bira-
cial/other were less likely to complete compared to white girls.
Girls were more likely to have completed the HPV vaccine in
2009 and 2010 compared to 2008. Flu vaccination was
associated with HPV vaccine completion. No regional differences
in completion of the HPV vaccine series were detected.
Stratified analyses of vaccine series initiation
and completion
In models stratified by region, vaccine initiation varied
depending on the respondent’s relationship with the child in
the South/Southwest (Table 4). Not having a primary care doc-
tor in the Northeast/Midwest/Western states was associated
with lower odds of initiation. Odds of initiating were similar in
the South/Southwest between those who had a primary care
doctor and those who did not. Younger children were less likely
to have initiated vaccination in both regions compared to 13–
17 y olds. Hispanic girls were more likely to have initiated vac-
cination in the South/Southwest, but no racial/ethnic differences
were observed in the other region. Girls were more likely to
have initiated in 2009 and 2010 compared to 2008 in the
South/Southwestern states. Vaccine initiation did not differ by
year in the Northeast/Midwest/Western regions, but odds were
higher with each year in the South/Southwest. Flu vaccination
was associated with HPV vaccine initiation in the both of the
regions observed.
Stratified analyses revealed that female respondents from the
Northeast/Midwest/West were almost 3 times more likely to
report that their child completed compared to males in the same
region, but gender was not associated with report of vaccine series
completion in the South/Southwest (Table 4). In the Northeast/
Midwest/West, respondents without a primary care doctor were
less likely to report the child had completed compared to those
who had one. Girls 11–12 y of age were less likely to have com-
pleted the vaccine series compared to 13–17 y olds in both
regions. Completion was similar across race/ethnicity in all
regions. Flu vaccination was associated with HPV vaccine series
completion in the South/Southwest, but was not significantly
associated with completion in the Northeast/Midwest/West.
Discussion
We found regional variations in HPV vaccine initiation
among 9–17 y olds. Girls in Northeast/Midwest/West states
were more likely to initiate than girls in the South/Southwest. It
was encouraging that no regional differences in vaccine comple-
tion among initiators were apparent, although completion was
low overall. These results mirror geographical HPV vaccination
disparities observed among women 18–26 y of age.9 In both
studies, girls in the South/Southwest were less likely to have initi-
ated vaccination than those in the Northeast and Midwest/West-
ern states.9 One difference between the 2 age groups is that
completion was lower in 18–26 y old women from the South/
Southwest compared to other regions, while regional differences
in completion were not found in this study. It should be noted
that we found lower rates of HPV vaccination among 13–17 y
olds compared to the NIS-Teen during the time period exam-
ined. During 2008–2010, NIS-Teen initiation rates were 37% in
2008, 44% in 2009 and 49% in 2010. 12,13 Completion among
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Table 1. Characteristics of adult respondents and 9–17 y olds(N D 7,849)
Total n
Weighted %
initiated HPV vaccine p-value n of initiators
Weighted % completed
HPV vaccine among initiatiorsa p-value
Adult respondent characteristics
Sex
Male 2,342 22.0 397 46.5
Female 5,507 28.9 <0.001 1,357 57.4 0.05
Relationship with child participants
Parent/ Guardian 7,042 26.3 1,583 55.6
Grandparent 405 40.7 99 49.7
Sibling or not related 397 25.4 0.009 71 51.6 0.78
Missing 5 34.9 1
Insurance status
Yes 6,453 27.9 1,452 57.0
No 1,371 23.2 0.03 298 48.5 0.12
Missing 25 20.8 4
Has primary care doctor
Yes 6,487 28.4 1,471 57.7
No 1,345 20.3 <0.001 277 46.2 0.05
Missing 17 75.4 6
Marital status
Married/partnered 5,607 24.8 1,189 54.3
Single 673 30.3 153 53.0
Separated/divorced/widowed 1,558 33.1 0.001 408 58.7 0.67
Missing 11 18.3 4
Education
<High school 771 28.7 185 53
High school graduate 2,023 28.2 447 53.7
Some college, college graduate 5,048 25.9 0.45 1,120 56.2 0.85
Missing 7 57.2 2
Employment
Employed 5,596 25.9 1,208 56.9
Not employed 882 34.7 298 44.4
Student/retired/homemaker 1,365 25.9 0.01 245 62.4 0.04
Missing 15 15.3 3
Child’s characteristics
Age (years)
9-10 1,497 5.3 54 42.8
11-12 1,653 22.4 265 40.9
13-17 4,699 36.9 <0.001 1,435 59.2 0.02
Total n Weighted % initiated HPV vaccinea p-value n Weighted % completed HPV vaccinea p-value
Race
White 5,585 25.9 1,195 58.1
Black 566 33.1 119 60.0
Hispanic 1,299 27.7 352 49.8
Biracial/ other 334 22.1 0.14 74 30.9 0.10
Missing 65 23.3 14
Control variables
BRFSS year
2008 2,897 24.9 375 42.3
2009 1,757 27.5 494 57.0
2010 3,195 28.7 0.19 885 58.7 0.02
Respondent or child received
flu vaccine in past 12 months
Yes 2,842 35.2 804 60.0
No 4,658 21.7 <0.001 855 51.2 0.05
Missing 349 36.1 95 45.1
Region
Northeast/Midwest/West 3,500 32.2 712 61.8
Connecticut 772 32.4 231 66.5
New York 478 35.3 - -
Pennsylvania 1,322 29.6 190 63.5
(continued on next page)
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13–17 y old initiators was also lower in our sample than in the
national sample.12 Reduced rates in the BRFSS are likely due to
uneven representation from southern states with lower odds of
initiating vaccination. Study year was associated with HPV vac-
cine initiation and completion, with each subsequent year
increasing in vaccination prevalence. This is in agreement with
findings from the NIS-Teen across time during the same time
period.12,13 However, it has been found that HPV vaccine com-
pletion among insured initiators has been decreasing with each
year of initiation.14 Prevalence rates are slow to reflect trends in
incidence, however. Recent data from NIS-Teen suggest that
completion of the vaccine series did not increase significantly
between 2011 (34.8%) and 2012 (33.4%), but indicate a modest
increase in 2013 (37.6%).10,15
Hispanic girls in our study were more likely to initiate vacci-
nation compared to white girls. However, the stratified analysis
shows that Hispanic girls were more likely than whites to have
initiated vaccination in the South/Southwest, but not in the
Northeast/Midwest/West. Hispanics have a high prevalence of
HPV infection, and are more likely to develop cervical cancer
than women of other races or ethnicities.16,17 Thus, the
increased odds of vaccination in Hispanic girls in the South/
Southwest may help to reduce some disparities in cervical cancer
between different racial/ethnic groups as well as between differ-
ent regions of the US. A high proportion of Hispanics living in
southern states are of Mexican descent and of more recent
immigration status, whereas Hispanics in other states repre-
sented in this study are more heterogeneous, which may provide
some explanation for the observed differences between
regions.18 Although there are several studies that examine
acceptability and knowledge of HPV among Hispanics, country
of origin is rarely considered as a factor in the choice for vacci-
nation. It is also possible that Hispanics in southern states are
more acculturated, and thus more likely to have their children
vaccinated.19 However, studies need to be conducted that focus
specifically on how country of origin and acculturation affect
the decision to have children vaccinated.
Respondents without a primary care provider had lower odds
of reporting that the sampled girl had initiated the HPV vac-
cine. In models stratified by region, girls in Northeast/Midwest/
West states were less likely to initiate and complete HPV
vaccination, while girls in the South/Southwest had similar odds
of initiating and completing regardless of whether they had a
primary care provider. Having a healthcare provider may indi-
cate an important point of contact for health information
among those living in Northeast/Midwest/West US states.
Healthcare counseling about the HPV vaccine has become an
important target in the efforts to get young girls and boys vacci-
nated.20 Although it is unknown why these differences exist, it
is possible that controversy surrounding proposed laws to
require the HPV vaccine, particularly in southern states such as
Texas and Virginia, have made the vaccine more prominent in
the media, thus increasing awareness in the South.21 Even
though this study shows that girls from southern states are less
likely to be vaccinated, widespread media coverage of the issue
may have the effect of making it less necessary for a doctor to
discuss the HPV vaccine with parents in order for them to
request it.
Flu vaccination of the respondent or the child was associated
with initiation in both regions and with completion in the
South/Southwest. This is consistent with other studies that show
flu vaccination is associated with HPV vaccination.22,23 It is pos-
sible that children who receive yearly flu vaccinations have
parents with more positive attitudes toward vaccination, and thus
have their children HPV vaccinated as well. In addition, flu vac-
cination may be a marker of children and adults who have regular
check-ups, and provided another point of contact with providers
to distribute vaccine-related information.
It was revealed that the younger age groups were less likely to
have ever initiated the HPV vaccine. Younger initiators were also
less likely to complete the series compared to the older (13–17 y
old) females. These findings indicate that 11–12 y olds were not
being fully vaccinated during the recommended age. Although it
could not be determined why, it has been found that 83% of all
health provider recommendations to vaccinate were made to
parents of 13–17 y old teens.24 Unfortunately, teens may have
been exposed to HPV by the time they reach 17 y of age. There-
fore, vaccination efforts in the US would be more effective if chil-
dren were routinely vaccinated at the recommended age of 11–12
y old, before potential exposure to HPV.
This study has some limitations. The BRFSS is a telephone
survey, and accuracy of the responses depended on participants’
Table 1. Characteristics of adult respondents and 9–17 y olds(N D 7,849) (Continued)
Total n
Weighted %
initiated HPV vaccine p-value n of initiators
Weighted % completed
HPV vaccine among initiatiorsa p-value
Wisconsin 256 33.6 74 52.1
Wyoming 672 29.5 217 63.6
South/Southwestb 4,349 23.6 <0.001 1,042 52.5 0.04
Delaware 276 31.9 88 53.6
Kentucky 427 32.1 116 60.1
Oklahoma 482 21.3 102 51.2
Texas 2,736 23.2 634 52.2
West Virginia 428 25.0 102 50.9
aWeighted proportion of girls who initiated or completed the HPV vaccine series.
bp-value reflects comparison between regions.
Abbreviations: Behavioral Risk Factor Surveillance System (BRFSS).
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self-report. There appears to be some response bias, as female
respondents were more likely to report that the child in their
household initiated and completed HPV vaccination. It is possi-
ble that the female respondents were more aware of the vaccina-
tion status of the girls in their households, or it is possible that
they were more likely to respond in a manner that was considered
more socially desirable. In addition, only 10 states participated in
the child HPV module, and all Northeast/Midwest/West states
did not include the number of vaccines received by the children
in the 2008 survey. However, the BRFSS is a survey with a rigor-
ous sampling strategy, and is representative of the households in
participating states.
This study has important implications for the Southern US,
as the states in this region have had low levels of screening with
high cervical cancer incidence and mortality.25 Increasing evi-
dence of low HPV vaccination means that the South/Southwest
Table 2.Multivariable logistic regression analysis of HPV vaccine initiation using weighted data
Adult respondent characteristics Model 1a Model 2a Model 3a
OR (95% CI) OR (95% CI) OR (95% CI)
Sex
Male Reference Reference
Female 1.38 (1.11-1.72)* 1.31 (1.05-1.63)*
Relationship with child
Parent/Guardian Reference Reference
Grandparent 1.51 (0.93-2.45) 1.90 (1.05-3.45)*
Sibling or not related 0.87 (0.55-1.39) 0.80 (0.50-1.27)
Insurance status
Yes Reference Reference
No 0.95 (0.71-1.27) 0.90 (0.66-1.24)
Has primary care doctor
Yes Reference Reference
No 0.76 (0.58-0.99)* 0.75 (0.56-1.00)
Marital status
Married/partnered Reference Reference
Single 1.28 (0.88-1.86) 1.20 (0.78-1.83)
Separated/divorced/widowed 1.39 (1.11-1.75)* 1.31 (1.01-1.70)
Education
<High school 1.29 (0.91-1.83) 0.97 (0.67-1.41)
High school graduate 1.14 (0.92-1.83) 1.06 (0.84-1.33)
Some college, college graduate Reference Reference
Employment
Employed Reference Reference
Not employed 1.33 (0.98-1.81) 1.27 (0.92-1.76)
Student/retired/homemaker 0.93 (0.73-1.19) 1.06 (0.84-1.33)
Child’s characteristics
Age (years)
9-10 0.09 (0.06-0.14)* 0.09 (0.06-0.13)*




Black 1.60 (1.07-2.40)* 1.44 (0.91-2.27)
Hispanic 1.41 (1.10-1.81)* 1.52 (1.14-2.03)*
Biracial/ other 0.81 (0.46-1.45) 0.83 (0.45-1.52)
Control variables
BRFSS year
2008 Reference Reference Reference
2009 1.21 (0.94-1.54) 1.25 (1.00-1.58) 1.28 (1.00-1.64)
2010 1.33 (1.07-1.64)* 1.26 (1.04-1.54)* 1.40 (1.14-1.73)*
Respondent or child received flu vaccine in past 12 months
Yes 2.27 (1.87-2.75)* 1.92 (1.60-2.31)* 2.17 (1.79-2.64)*
No Reference Reference Reference
Region
Northeast/Midwest/West 1.78 (1.48-2.15)* 1.58 (1.32-1.88)* 1.78 (1.47-2.15)*
South/Southwest Reference Reference Reference
aModel 1: child variables, Model 2: respondent variables, and Model 3: respondent and child variables.
*Indicates significance at P < 0.05.
Abbreviations: Behavioral Risk Factor Surveillance System (BRFSS).
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could continue to experience a high burden of HPV-related
cancers, and even serve as a reservoir for vaccine-type HPV as
decreases in HPV-related disease incidence becomes more
apparent in other states over the next several decades. Further,
this study demonstrates that simply controlling for region may
obscure regional variations in characteristics associated with vac-
cination. To better understand geographical disparities in vacci-
nation, more detailed research examining the effect of state
legislation, marketing, funding for free vaccines and regional
cultural influences on HPV vaccination are needed.
Methods
Data and study selection
Individual-level data were obtained from the public-use data
files of the 2008–2010 BRFSS.26 The survey was a random
digit dial telephone survey of non-institutionalized adults in the
US. Children were selected randomly for every household with
at least 1 child under the age of 18 y. All child data was pro-
vided by an adult proxy, referred to in this study as the respon-
dent. The methods and response rates for the BRFSS are
Table 3.Multivariable logistic regression to determine odds of characteristics associated with HPV vaccine completion among initiators using weighted data
Respondent characteristics Model 1a Model 2a Model 3a
Sex
Male Reference Reference
Female 2.22 (1.41-3.49)* 2.22 (1.41-3.49)*
Relationship with child
Parent/Guardian Reference Reference
Grandparent 1.10 (0.44-2.78) 1.10 (0.44-2.78)
Sibling or not related 0.83 (0.32-2.19) 0.58 (0.27-1.24)
Insurance status
Yes Reference Reference
No 0.92 (0.50-1.69) 0.92 (0.50-1.69)
Has primary care doctor
Yes Reference Reference
No 0.66 (0.38-1.15) 0.66 (0.38-1.15)
Marital status
Married/partnered Reference Reference
Single 0.58 (0.27-1.24) 0.58 (0.27-1.24)
Separated/divorced/widowed 0.89 (0.55-1.44) 0.89 (0.55-1.44)
Education
<High school 1.29 (0.66-2.50) 1.24 (0.64-2.42)
High school graduate 1.06 (0.71-1.58) 1.06 (0.71-1.58)
Some college, college graduate Reference Reference
Employment
Employed Reference Reference
Not employed 1.36 (0.72-2.54) 1.35 (0.72-2.56)
Student/retired/homemaker 0.65 (0.41-1.04) 0.69 (0.43-1.00)
Child’s characteristics
Age (years)
9-10 0.63 (0.26-1.55) 0.68 (0.27-1.70)




Black 1.26 (0.58-2.73) 1.18 (0.50-2.80)
Hispanic 0.78 (0.50-1.22) 0.87 (0.52-1.47)
Biracial/ other 0.35 (0.15-0.80)* 0.32 (0.14-0.76)*
Control variables
BRFSS year
2008 Reference Reference Reference
2009 1.59 (0.89-2.84) 1.88 (1.06-3.34)* 1.92 (1.08-3.40)*
2010 1.69 (1.01-2.83)* 1.85 (1.11-3.06)* 1.86 (1.12-3.07)*
Respondent or child received flu vaccine in past 12 months
Yes 1.45 (1.01-2.09)* 1.57 (1.09-2.26)* 1.55 (1.08-2.22)*
No Reference Reference Reference
Region
Northeast/Midwest/West 1.22 (0.80-1.87) 1.18 (0.78-1.78) 1.18 (0.78-1.78)
South/Southwest Reference Reference Reference
a Model 1:child variables, Model 2: respondent variables, and Model 3: respondent and child variables.
*Significance at P < 0.05.
Abbreviations: Behavioral Risk Factor Surveillance System (BRFSS).
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available in greater detail on the BRFSS documentation
website.26
Girls 9–17 y of age were eligible to be included. Respondents
must have answered “yes” or “no” to the vaccine initiation ques-
tion for the selected female child. Of 8,872 eligible females, 798
of the survey respondents did not know or refused to answer
whether the child had been vaccinated. Also, children without
age data were excluded from the study (n D 225). Total sample
size was 7,849 girls after applying the exclusion criteria.
A total of 10 states participated in the child HPV vaccination
survey at least one time during the 3 survey years. These states
were divided into 2 regions to examine variation in vaccine
Table 4. Multivariable logistic regression to determine odds of characteristics associated with HPV vaccine series initiation and completion among initiators
using weighted data, by region
Northeast/Midwest/West South/Southwest
Initiation Completion Initiation Completion
Adult respondent characteristics
Sex
Male Reference Reference Reference Reference
Female 1.05 (0.79-1.40) 2.87 (1.63-5.07)* 1.57 (1.14-2.18)* 1.83 (1.00-3.36)
Relationship with child
Parent/Guardian Reference Reference Reference Reference
Grandparent 1.03 (0.52-2.07) 0.55 (0.15-2.07) 2.30 (1.13-4.69)* 2.08 (0.66-6.57)
Sibling or not related 1.01 (0.54-1.88) 1.08 (0.22-5.32) 0.50 (0.25-0.99)* 0.84 (0.28-2.48)
Insurance status
Yes Reference Reference Reference Reference
No 0.81 (0.45-1.45) 1.64 (0.51-5.30) 0.92 (0.63-1.34) 0.79 (0.40-1.57)
Has primary care doctor
Yes Reference Reference Reference Reference
No 0.53 (0.32-0.87)* 0.21 (0.07-0.63)* 0.84 (0.59-1.19) 0.77 (0.42-1.40 )
Marital status
Married/partnered Reference Reference Reference Reference
Single 0.81 (0.57-1.14) 0.49 (0.22-1.08) 0.76 (0.54-1.09) 1.01 (0.38-2.72)
Separated/divorced/widowed 1.24 (0.71-2.17) 0.21 (0.07-0.63)* 0.80 (0.42-1.52) 1.01 (0.56-1.80)
Education
<High school 1.40 (0.73-2.69) 0.46 (0.12-1.73) 0.85 (0.53-1.36) 1.53 (0.73-3.22)
High school graduate 0.95 (0.69-1.56) 1.05 (0.60-1.83) 1.18 (0.86-1.62) 1.15 (0.69-1.92)
Some college, college graduate Reference Reference Reference Reference
Employment
Employed Reference Reference Reference Reference
Not employed 1.04 (0.70-1.56) 1.47 (0.63-3.42) 1.45 (0.91-2.32) 1.36 (0.63-2.94)
Student/retired/homemaker 0.98 (0.69-1.39) 0.52 (0.27-1.02) 1.06 (0.75-1.50) 0.76 (0.43-1.34)
Control variables
BRFSS year
2008 Reference Reference 0.57 (0.34-0.97)*
2009 1.06 (0.77-1.47) 0.92 (0.54-1.57) 1.59 (1.12-2.24)* 1.10 (0.64-1.89)
2010 0.84 (0.63-1.13) Reference 1.96 (1.46-2.64)* Reference
Respondent or child received flu vaccine in past 12 months
Yes 1.95 (1.49-2.54)* 1.12 (0.67-1.81) 2.43 (1.85-3.20)* 1.68 (1.08-2.64)*
No Reference Reference Reference Reference
Child’s characteristics
Age (years)
9-10 0.06 (0.03-0.10)* 1.05 (0.23-4.80) 0.10 (0.06-0.17)* 0.61 (0.22-1.71)
11-12 0.34 (0.24-0.46)* 0.31 (0.16-0.60)* 0.61 (0.44-0.85)* 0.38 (0.21-0.71)*
13-17 Reference Reference Reference Reference
Race
White Reference Reference Reference Reference
Black 1.00 (0.61-1.64) 0.47 (0.17-1.30) 1.59 (0.85-2.96) 1.74 (0.64-4.74)
Hispanic 1.11 (0.62-1.98) 1.93 (0.62-6.05) 1.57 (1.13-2.18)* 0.81 (0.45-1.47)
Biracial/ other 0.66 (0.29-1.51) 0.33 (0.07-1.48) 0.95 (0.39-2.33) 0.30 (0.11-0.83)
Northeast/Midwest/West South/Southwest
Initiation Completion Initiation Completion
Received flu vaccine in past 12 months
Yes 1.95 (1.49-2.54)* 1.12 (0.67-1.81) 2.43 (1.85-3.20)* 1.68 (1.08-2.64)*
No Reference Reference Reference Reference
*Significance at P < 0.05.
Abbreviations: Behavioral Risk Factor Surveillance System (BRFSS).
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initiation and completion. Regions included: Northeast/Mid-
west/West (CT, NY, PA, WI, WY), and South/Southwest (DE,
KY, OK, TX, WV). States were combined into 2 regions in order
to achieve adequate power for analyses. In 2008, DE, NY, OK,
PA, TX, and WV included the child HPV questions, in 2009,
CT, TX, WI, and WY included these questions, and in 2010
CT, KY, PA, TX, WV, and WY included child HPV vaccine
questions in their state survey. States in the Northeast/Midwest/
West region did not include questions about the number of
HPV vaccinations received in the 2008 survey. This study was
exempt from full review by the University of Texas Medical
Branch and the University of North Carolina at Chapel Hill
Institutional Review Boards.
Measures
Dichotomous dependent variables included: HPV vaccine ini-
tiation and completion. Initiation was determined using the
question: “A vaccine to prevent the human papillomavirus or
HPV infection is available and is called cervical cancer vaccine,
HPV shot, GARDASIL, or Cervarix. Has this child EVER had
the HPV vaccination?” Initiation was determined to have
occurred if respondents answered “yes” and then indicated that
the selected child received one vaccine dose. Responses were
binary, with children who received 1 dose assigned a value of 1,
and those who reported no vaccination assigned a value of 0. For
completion, children who had initiated and received 3 doses of
the HPV vaccine were assigned 1 and those with fewer than 3
doses were assigned 0.
Characteristics of both respondent and the child were
included in the analyses. Characteristics for the respondent
included: sex (male or female), relationship to the child (parent/
guardian, grandparent, sibling or unrelated to child), insurance
coverage, whether they had a primary care doctor, marital status
(married/ partnered, single-never married, separated/ divorced/
widowed), and education level (<high school, graduated high
school, attended some college or college graduate). For relation-
ship, respondents were asked, “How are you related to the child?”
Possible responses included: parent (biologic, step, or adoptive),
foster parent or guardian, grandparent, sibling (biologic, step, or
adoptive), other relative, and not related in any way. Responses
were collapsed into 3 categories, with parent/guardian including
parents and foster parents or guardians, grandparents in a sepa-
rate category, and sibling/other included the remainder of the
possible responses.
Child characteristics included: age (9–10, 11–12, and 13–17 y
of age) and race/ ethnicity (white, black, Hispanic, biracial/
other). Age was categorized to reflect current guidelines for vacci-
nation, which include the recommendation that children be vac-
cinated at 11–12 y of age, but can be vaccinated as young as 9 y
old with catch-up vaccination up to 26 y of age. Children were
categorized Hispanic if the adult respondent answered “yes” to
the question, “Is the child Hispanic or Latino?” To determine
race, the adult respondent was asked, “Which one or more of the
following would you say is the race of the child?” Children who
were white but not Hispanic were categorized as white. Children
who were black or African American but not Hispanic were
categorized as black. Children who were Native Hawaiian or
other Pacific Islander, American Indian, Alaska Native, other, or
who were biracial were included into the biracial/other category.
We also included other variables in the model such as: region,
the year the BRFSS was conducted (2008, 2009, 2010), and
whether the child or respondent received the flu vaccine (injec-
tion or nasal spray) in the past year.
Statistical analyses
Data was weighted using child weights to calculate propor-
tions in order to make the results more generalizable to children
in the US. Rao-Scott Ratio Chi-Square Tests were used to exam-
ine differences between categorical variables in the descriptive
analyses and to test for interaction effects. Multivariable logistic
regression models estimated the odds for initiating and complet-
ing HPV vaccination among initiators. For these analyses, 3
models were used to examine regional differences in initiation
and completion of the HPV vaccine series. The first model
included the child’s characteristics, and shared characteristics,
which consisted of: region of the household, the survey year, and
receipt of the flu vaccine. The second model included the respon-
dent characteristics and shared characteristics. The third model
included all variables. These models were used to determine
whether inclusion of child or respondent characteristics changed
the association between region and vaccination substantially. A
model with main effects and interaction terms for region and all
other characteristics was tried. Since several interaction terms
were significant, 2 region-specific models were built by stratifying
the final analyses by region. Stratification by region allowed the
observation of differences in associations between characteristics
and vaccination between regions. All analyses were conducted
using SAS software version 9.3 (Cary, NC).
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